Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab

Immunoglobulin E and its interactions with receptors FcϵRI and CD23 play a central role in allergic disease. Omalizumab, a clinically approved therapeutic antibody, inhibits the interaction between IgE and FcϵRI, preventing mast cell and basophil activation, and blocks IgE binding to CD23 on B cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Anna M., Allan, Elizabeth G., Keeble, Anthony H., Delgado, Jean, Cossins, Benjamin P., Mitropoulou, Alkistis N., Pang, Marie O. Y., Ceska, Tom, Beavil, Andrew J., Craggs, Graham, Westwood, Marta, Henry, Alistair J., McDonnell, James M., Sutton, Brian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2017
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473249/
https://www.ncbi.nlm.nih.gov/pubmed/28438838
http://dx.doi.org/10.1074/jbc.M117.776476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473249/
https://www.ncbi.nlm.nih.gov/pubmed/28438838
http://dx.doi.org/10.1074/jbc.M117.776476

Ejemplares similares